Top 55 Most-Cited Articles Published in *The Oncologist* 2010 and 2011

The Oncologist is deeply committed to its mission to further the practice of oncology by publishing papers that have direct practical application in the clinic. We thank the authors of the following papers, which represent our most highly cited articles from 2010 and 2011, and our readers, who use this knowledge in their everyday practice of oncology.

BREAST CANCER

In the End What Matters Most? A Review of Clinical Endpoints in Advanced Breast Cancer

Sunil Verma et al.; 10.1634/theoncologist.2010-0278.

Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer

Leonel F. Hernandez-Aya et al.; 10.1634/theoncologist.2010-0402.

Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor-Positive Metastatic Breast Cancer

Lee S. Schwartzberg et al.; 10.1634/theoncologist.2009-0240.

Lapatinib Plus Capecitabine in Women with HER-2-Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

David Cameron et al.; 10.1634/theoncologist.2009-0181.

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Jean-Marc Extra et al.; 10.1634/theoncologist.2009-0029.

Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer

Daphne T. Tsoi et al.; 10.1634/theoncologist.2009-0275

Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis

Lajos Pusztai et al.; 10.1634/theoncologist.2010-0059.

Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review

Lee S. Rosen et al.; 10.1634/theoncologist.2009-0145.

Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers

Jacqueline Lehmann-Che et al.; 10.1634/theoncologist.2009-0243.

A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium

Sara K. Taylor et al.; 10.1634/theoncologist.2010-0081.

CANCER BIOLOGY

Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

Christos Vaklavas et al.; 10.1634/theoncologist.2009-0252.

CANCER DIAGNOSTICS AND MOLECULAR PATHOLOGY

Systemic miRNA-195 Differentiates Breast Cancer from Other Malignancies and Is a Potential Biomarker for Detecting Noninvasive and Early Stage Disease

Helen M. Heneghan et al.; 10.1634/theoncologist.2010-0103.

ENDOCRINOLOGY

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer

Carmelo Nucera et al.; 10.1634/theoncologist.2010-0317.

Risk of Cancer Following Hospitalization for Type 2 Diabetes

Kari Hemminki et al.; 10.1634/theoncologist.2009-0300.

Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer

Christine J. O'Neill et al.; 10.1634/theoncologist.2009-0190.

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer

Adrienne L. Melck et al.; 10.1634/theoncologist.2010-0156.

GASTROINTESTINAL CANCER

External Quality Assessment for KRAS Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds

Ellen Bellon et al.; 10.1634/theoncologist.2010-0429.

Addition of Bevacizumab to XELOX Induction Therapy Plus Concomitant Capecitabine-Based Chemoradiotherapy in Magnetic Resonance Imaging-Defined Poor-Prognosis Locally Advanced Rectal Cancer: The AVACROSS Study

Miguel Nogué et al.; 10.1634/theoncologist.2010-0285.

Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery

Sabine Tejpar et al.; 10.1634/theoncologist.2009-0233.

A Review of the Most Promising Biomarkers in Colorectal Cancer: One Step Closer to Targeted Therapy

Vanessa Deschoolmeester et al.; 10.1634/theoncologist.2010-0025.

The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development

Cathy Eng; 10.1634/theoncologist.2009-0167

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

Dan G. Duda et al.; 10.1634/theoncologist.2010-0029.

A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal Cancer

Christopher G. Willett et al.; 10.1634/theoncologist.2010-0030.

Chemoradiation in Pancreatic Adenocarcinoma: A Literature Review

Rajarshi Roy et al.; 10.1634/theoncologist.2009-0272.

GENITOURINARY CANCER: PROSTATE

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

Ravi A. Madan et al.; 10.1634/theoncologist.2010-0129.

GERIATRIC ONCOLOGY

Polypharmacy in Older Adults with Cancer

Ronald J. Maggiore et al.; 10.1634/theoncologist.2009-0290.

How Does Older Age Influence Oncologists' Cancer Management?

Jill A. Foster et al.; 10.1634/theoncologist.2009-01980

GYNECOLOGIC ONCOLOGY

Analysis of Morbidity and Clinical Implications of Laparoscopic Para-Aortic Lymphadenectomy in a Continuous Series of 98 Patients with Advanced-Stage Cervical Cancer and Negative PET-CT Imaging in the Para-Aortic Area

Catherine Uzan et al.; 10.1634/theoncologist.2011-0007.

Prognostic Factors and Morbidities After Completion Surgery in Patients Undergoing Initial Chemoradiation Therapy for Locally Advanced Cervical Cancer

Cyril Touboul et al.; 10.1634/theoncologist.2009-0295.

Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

Katherine M. Moxley et al.; 10.1634/theoncologist.2010-0087.

HEAD AND NECK CANCERS

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

Gemma Pueyo et al.; 10.1634/theoncologist.2008-0290.

HEPATOBIILIARY

Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)

Dieter Koeberle et al.; 10.1634/theoncologist.2009-0316.

Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study

Jean-François Dufour et al.; 10.1634/theoncologist.2010-0180.

Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

Bruno Vincenzi et al.; 10.1634/theoncologist.2009-0143.

Current Management of Gallbladder Carcinoma

Andrew X. Zhu et al.; 10.1634/theoncologist.2009-0302.

LEUKEMIAS

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma

Marshall A. Lichtman; 10.1634/theoncologist.2010-0206.

LUNG CANCER

Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions

Randeep Sangha et al.; 10.1634/theoncologist.2009-0186.

Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms

Thomas E. Stinchcombe et al.; 10.1634/theoncologist.2009-0298.

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer

Nicholas Thatcher et al.; 10.1634/theoncologist.2009-0292.

LYMPHOMA

Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic Lymphoma

Jorge J. Castillo et al.; 10.1634/theoncologist.2009-0304.

MYELOMAS

Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Heinz Ludwig et al.; 10.1634/theoncologist.2009-0203.

NEURO-ONCOLOGY

Review on Quality of Life Issues in Patients with Primary Brain Tumors

Martin J.B. Taphoorn et al.; 10.1634/theoncologist.2009-0291.

NEW DRUG DEVELOPMENT

CLINICAL PHARMACOLOGY

Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers

Alex A. Adjei et al.; 10.1634/theoncologist.2010-0380.

Combining Targeted Therapies: Practical Issues to Consider at the Bench and Bedside

Jordi Rodon et al.; 10.1634/theoncologist.2009-0117.

Inhibitors of mTOR

Heinz-Josef Klümper et al.; 10.1634/theoncologist.2010-0196.

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

Paul Hamberg et al.; 10.1634/theoncologist.2009-0274.

OUTCOMES RESEARCH

Obesity and Cancer

Kathleen Y. Wolin et al.; 10.1634/theoncologist.2009-0285.

Conditional Survival Among Cancer Patients in the United States

Ray M. Merrill et al.; 10.1634/theoncologist.2009-0211

RADIATION ONCOLOGY

Radiation Recall with Anticancer Agents

Howard A. Burris III et al.; 10.1634/theoncologist.2009-0090.

REGULATORY ISSUES: FDA

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

Virginia E. Kwitkowski et al.; 10.1634/theoncologist.2009-0178.

FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma

Jeff Summers et al.; 10.1634/theoncologist.2009-0250.

Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors

Martin H. Cohen et al.; 10.1634/theoncologist.2009-0120

SYMPTOM MANAGEMENT AND SUPPORTIVE CARE

Association Between a Name Change from Palliative to Supportive Care and the Timing of Patient Referrals at a Comprehensive Cancer Center

Shalini Dalal et al.; 10.1634/theoncologist.2010-0161.

Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer

Giovanni Mantovani et al.; 10.1634/theoncologist.2009-0153.

How Accurate Are Physicians in the Prediction of Patient Survival in Advanced Lung Cancer?

Christelle Clément-Duchêne et al.; 10.1634/theoncologist.2009-0149.

©AlphaMed Press 1083-7159/2012/\$20.00/0 <http://dx.doi.org/10.1634/theoncologist.2012-0385>